Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

NOT_YET_RECRUITING

RVU120 Rollover Study

Lead Sponsor:

Ryvu Therapeutics SA

Conditions:

Advanced Solid Tumors

Acute Myeloid Leukaemia (AML)

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the t...

Detailed Description

Participants may continue treatment until loss of clinical benefit as judged by the investigator, unacceptable toxicity, start of subsequent anticancer therapy, or until any other criterion for withdr...

Eligibility Criteria

Inclusion

  • The participant is enrolled in a RVU120 clinical study and receiving RVU120-based treatment given alone or in combination for at least 5 cycles.
  • The participant is currently benefiting from, and expected to continue to benefit from, RVU120-based treatment according to the criteria set out in the parent study protocol and according to the judgment of the investigator and sponsor.
  • The participant does not have access to commercially available comparator anticancer therapy.
  • Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • The participant signed the rollover study ICF prior to any study-related procedure or study data collection.
  • The participant agrees not to donate blood during study participation and until 28 weeks (\~6.5 months) after the last dose.
  • The investigator considers the participant to be eligible for participation in the rollover study.

Exclusion

  • Presence of toxicity that cannot be adequately managed.
  • Concurrent participation in any therapeutic clinical study other than the parent study.

Key Trial Info

Start Date :

December 15 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2026

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT06987058

Start Date

December 15 2025

End Date

August 1 2026

Last Update

September 24 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Uniwersyteckie Centrum Kliniczne

Gdansk, Poland, 80-214

2

Clinica Universidad de Navarra

Pamplona, Spain, 31008